News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus
Top-line Data Readout Expected in Q2, 2019 STAMFORD, Conn. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively
View HTML
Toggle Summary Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
-  Trial continues as planned with enrollment target of 350 patients  - -  Top-line data readout expected in the first half of 2019  - STAMFORD, Conn. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new
View HTML
Toggle Summary Cara Therapeutics to Present at November Investor Conferences
STAMFORD, Conn. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Third Quarter 2018 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
STAMFORD, Conn. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer
- Former VP of Medical Affairs for Dermatology at Celgene to lead development of KORSUVA™ in dermatological conditions - STAMFORD, Conn. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical
View HTML
Toggle Summary Cara Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
STAMFORD, Conn. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress
STAMFORD, Conn. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Second Quarter 2018 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting
View HTML
Toggle Summary Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
KALM™-2 trial to evaluate the efficacy of KORSUVA™ injection at 12 weeks STAMFORD, Conn. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by
View HTML